Undetected toxicity risk in pharmacogenetic testing for dihydropyrimidine dehydrogenase

• Published in: International Journal of Molecular Sciences 2015-04, Vol.16 (4), p.8884-8895
• Main Authors: Falvella, Felicia Stefania, Caporale, Marta, Cheli, Stefania, Martinetti, Antonia, Berenato, Rosa, Maggi, Claudia, Niger, Monica, Ricchini, Francesca, Bossi, Ilaria, Di Bartolomeo, Maria, Sottotetti, Elisa, Bernardi, Francesca Futura, de Braud, Filippo, Clementi, Emilio, Pietrantonio, Filippo
• Format: Article
• Language: English
• Subjects: Animals; Antimetabolites, Antineoplastic - adverse effects; Antimetabolites, Antineoplastic - therapeutic use; Chemotherapy; Colorectal Neoplasms - drug therapy; dihydropyrimidine dehydrogenase; Dihydrouracil Dehydrogenase (NADP) - genetics; Enzymes; Epigenesis, Genetic; fluoropyrimidines; Fluorouracil - adverse effects; Fluorouracil - therapeutic use; Gene Frequency; Genotype & phenotype; Humans; pharmacogenetics; Polymorphism, Single Nucleotide; Review; Risk factors; single nucleotide polymorphisms; Toxicity
• ISSN: 1422-0067; 1661-6596; 1422-0067
• DOI: 10.3390/ijms16048884

Fluoropyrimidines, the mainstay agents for the treatment of colorectal cancer, alone or as a part of combination therapies, cause severe adverse reactions in about 10%-30% of patients. Dihydropyrimidine dehydrogenase (DPD), a key enzyme in the catabolism of 5-fluorouracil, has been intensively investigated in relation to fluoropyrimidine toxicity, and several DPD gene (DPYD) polymorphisms are associated with decreased enzyme activity and increased risk of fluoropyrimidine-related toxicity. In patients carrying non-functional DPYD variants (c.1905+1G>A, c.1679T>G, c.2846A>T), fluoropyrimidines should be avoided or reduced according to the patients' homozygous or heterozygous status, respectively. For other common DPYD variants (c.496A>G, c.1129-5923C>G, c.1896T>C), conflicting data are reported and their use in clinical practice still needs to be validated. The high frequency of DPYD polymorphism and the lack of large prospective trials may explain differences in studies' results. The epigenetic regulation of DPD expression has been recently investigated to explain the variable activity of the enzyme. DPYD promoter methylation and its regulation by microRNAs may affect the toxicity risk of fluoropyrimidines. The studies we reviewed indicate that pharmacogenetic testing is promising to direct personalised dosing of fluoropyrimidines, although further investigations are needed to establish the role of DPD in severe toxicity in patients treated for colorectal cancer.